Cancer Cell

• 

  Publication Venue For

  • Metabolic programming and immune suppression in the tumor microenvironment..  41:421-433. 2023
  • A path to translation: How 3D patient tumor avatars enable next generation precision oncology..  40:1448-1453. 2022
  • Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts..  40:1521-1536.e7. 2022
  • Cancer vaccines..  40:559-564. 2022
  • Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy..  40:674-693.e7. 2022
  • Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition..  40:439-440. 2022
  • Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells..  40:545-557.e13. 2022
  • B cells and cancer..  39:1293-1296. 2021
  • Tumor heterogeneity..  39:1015-1017. 2021
  • The Landscape of Cell and Gene Therapies for Solid Tumors..  39:7-8. 2021
  • A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance..  38:761-766. 2020
  • MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate..  38:60-78.e12. 2020
  • Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis..  36:319-336.e7. 2019
  • Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies..  36:17-34.e7. 2019
  • Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors..  35:885-900.e10. 2019
  • Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes..  35:932-947.e8. 2019
  • Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets..  35:588-602.e10. 2019
  • Serine and Methionine Metabolism: Vulnerabilities in Lethal Prostate Cancer..  35:339-341. 2019
  • Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner..  34:513-528.e8. 2018
  • Biological Role and Therapeutic Potential of IDH Mutations in Cancer..  34:186-195. 2018
  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients..  34:211-224.e6. 2018
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers..  33:690-705.e9. 2018
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas..  33:721-735.e8. 2018
  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy..  33:676-689.e3. 2018
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer..  33:706-720.e9. 2018
  • Glucose Metabolism in Cancer: The Saga of Pyruvate Kinase Continues..  33:337-339. 2018
  • Neomorphic ERα Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery..  33:153-155. 2018
  • Genomic and Epigenomic Profiling of High-Risk Intestinal Metaplasia Reveals Molecular Determinants of Progression to Gastric Cancer..  33:137-150.e5. 2018
  • MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition..  31:270-285. 2017
  • ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis..  31:35-49. 2017
  • Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer..  30:120-135. 2016
  • RIPK3 Slams the Brake on Leukemogenesis..  30:7-9. 2016
  • N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells..  29:536-547. 2016
  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B..  29:49-60. 2016
  • Erythropoietin Stimulates Tumor Growth via EphB4..  28:610-622. 2015
  • Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules..  28:82-96. 2015
  • Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation..  27:27-40. 2015
  • Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer..  26:840-850. 2014
  • EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma..  26:668-681. 2014
  • Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells..  26:623-637. 2014
  • Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition..  25:393-405. 2014
  • RAS and ROS in rhabdomyosarcoma..  24:689-691. 2013
  • Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy..  24:30-44. 2013
  • Releasing the block: setting differentiation free with mutant IDH inhibitors..  23:570-572. 2013
  • Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models..  23:121-128. 2013
  • STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation..  22:466-478. 2012
  • TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma..  22:291-303. 2012
  • In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma..  21:680-693. 2012
  • An animal model of MYC-driven medulloblastoma..  21:155-167. 2012
  • The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer..  20:500-510. 2011
  • Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth..  19:792-804. 2011
  • Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3..  19:498-511. 2011
  • CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation..  18:485-498. 2010
  • An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction..  18:231-243. 2010
  • IDH1 and IDH2: not your typical oncogenes..  17:215-216. 2010
  • Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate..  16:336-346. 2009
  • Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors..  16:126-136. 2009
  • AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer..  16:21-32. 2009
  • Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells..  15:501-513. 2009
  • Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment..  15:527-538. 2009
  • Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma..  15:135-147. 2009
  • Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. 2018